The trial did not meet its primary endpoint of overall survival
The prespecified subgroup of patients treated with eryaspase and an irinotecan-based chemotherapy demonstrated an interesting trend of survival benefit, which merits further investigation
Patients treated with eryaspase demonstrated superior disease control compared to patients treated with chemotherapy only. Other secondary endpoints showed nominal improvement
The safety profile of eryaspase was consistent with earlier clinical trials results and safety reviews
ERYTECH will now focus on its late-stage program in hypersensitive ALL and confirms its intention to submit a BLA before the end of the year
ERYTECH will review strategic and partnering alternatives, including for the further development and commercialization of eryaspase
at 8:30am EDT/ 2:30pm CEST
TRYbeCA-1 Top-line Results and Analysis Conference Call Details
ERYTECH management will hold a conference call and webcast on October 25, at 8:30am EDT / 2:30 pm CEST highlights the top-line results and plans for future approval and launch in 2022. Gil Beyen, CEO, Eric Soyer, CFO/COO, and Iman El-Hariry, CMO, will deliver a brief presentation, followed by a Q&A session.
The audio call is accessible via the below registering link: http://www.directeventreg.com/registration/event/2361482 (Conference ID : 2361482). Once registered, participants will receive a unique access code and the call number details to join the teleconference.
The webcast can be followed live online via the link: https://edge.media-server.com/mmc/p/4cdxqddy
An archive of the webcast will be available on ERYTECH’s website, under the “Investors” section at investors.erytech.com
An archived replay of the audio call will be available for 7 days by dialing + 1 855 859 2056, Conference ID: 2361482#.
https://finance.yahoo.com/news/erytech-announces-results-trybeca-1-050000479.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.